Carlsmed Secures $52.5M in Series C Funding to Revolutionize Personalized Spine Surgery

Carlsmed, a commercial-stage medical technology leader and pioneer in the personalized spine surgery market, has recently secured USD 52.5 million in new funding—a significant milestone that will accelerate its mission of transforming spine surgery. With the cutting-edge aprevo® Technology Platform at its core, Carlsmed continues to push the boundaries of innovation by combining proprietary AI-driven software with patient-specific fusion devices, ensuring that each surgical procedure is tailored to the unique needs of every patient. This substantial infusion of capital will be dedicated to further refining its groundbreaking technology, expanding clinical trials, and expediting regulatory submissions to bring new solutions to market faster. The funding also supports strategic growth initiatives, including the scaling of manufacturing operations and an expansion of the company’s global footprint, thereby positioning Carlsmed to solidify its leadership role in revolutionizing spine surgery. In addition to ramping up research and development, the investment will help foster key partnerships and collaborations with leading healthcare institutions and industry experts, ensuring that Carlsmed remains at the forefront of advances in personalized medical treatment. As the healthcare landscape continues to evolve, Carlsmed’s commitment to merging innovative technology with surgical precision sets a new standard in patient care, promising enhanced outcomes and safety for individuals undergoing spinal procedures. This latest funding round is not only a vote of confidence in Carlsmed’s visionary approach but also a catalyst for continued breakthroughs that will shape the future of spine surgery worldwide.